Lisata Therapeutics and WARPNINE unveil positive preliminary results from pancreatic cancer trial
Lisata Therapeutics Inc (NASDAQ:LSTA) and WARPNINE have announced promising preliminary results from their Phase 1b/2a iLSTA trial, which is evaluating Lisata's investigational drug certepetide in combination with standard-of-care chemotherapy and immunotherapy for locally advanced non-resectable pancreatic ductal adenocarcinoma (PDAC). The iLSTA trial is being conducted at St John of God Subiaco Hospital in Western Australia, involving 30 patients divided into three treatment cohorts.
Lisata Therapeutics unveils encouraging preliminary data from Phase 2 pancreatic cancer trial
Lisata Therapeutics Inc (NASDAQ:LSTA) has reported encouraging preliminary data for Cohort A of its ongoing ASCEND Phase 2 trial. The trial, conducted across 25 sites in Australia and New Zealand, is evaluating the efficacy of Lisata's novel therapy certepetide in combination with standard-of-care chemotherapy for the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC), an aggressive form of pancreatic cancer.
Lisata Therapeutics advances certepetide with trial enrollment milestone and new diagnostic partnership
Lisata Therapeutics Inc (NASDAQ:LSTA) shares were reacting positively this week after the company announced further developments for its lead investigational drug candidate, certepetide. The company announced the completion of patient enrollment in the Phase 1b/2a CENDIFOX trial, evaluating its iRGD cyclic peptide, certepetide, with FOLFIRINOX-based therapies for pancreatic, colon, and appendiceal cancers.
Lisata Therapeutics completes patient enrollment for CENDIFOX trial
Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has completed patient enrollment in all three cohorts of its Phase 1b/2a CENDIFOX trial evaluating the safety and efficacy of Lisata's investigational drug certepetide in combination with FOLFIRINOX-based therapies for pancreatic, colon and appendiceal cancers. Certepetide is a cyclic peptide designed to enhance the delivery of anti-cancer drugs by activating a unique pathway that helps them target and penetrate solid tumors more effectively.
Lisata Therapeutics and Kuva Labs to collaborate on cancer imaging solution
Lisata Therapeutics Inc (NASDAQ:LSTA) has announced a collaboration and license agreement with Kuva Labs, a wholly owned subsidiary of Mi2 Holdings. The clinical-stage pharmaceutical firm said the agreement will give Kuva access to Lisata's iRGD cyclic peptide, certepetide, as a targeting and delivery agent for their NanoMark platform to create a new class of advanced magnetic resonance (MR) imaging agents for the detection of solid tumor cancers.
Lisata Therapeutics named ‘Specialized BioTherapeutics Company of the Year' at 2024 BioTech Breakthrough Awards
Lisata Therapeutics Inc (NASDAQ:LSTA) has been awarded the title of ‘Specialized BioTherapeutics Company of the Year' at the 2024 BioTech Breakthrough Awards. The company said it was recognized for its unique approach to addressing the unmet medical needs of patients with advanced solid tumors, particularly through its proprietary CendR Platform technology which enhances the delivery and efficacy of anti-cancer treatments by targeting the tumor microenvironment.
Lisata Therapeutics CEO discusses pancreatic cancer trial progress and new collaborations - ICYMI
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo joined Proactive to talk about the latest updates on its clinical trials and its third quarter financial performance. Mazzo highlighted advancements in Lisata's pancreatic cancer program, specifically the ASCEND trial, which is expected to yield important data soon.
Lisata Therapeutics, Inc. (LSTA) Q3 2024 Earnings Call Transcript
Lisata Therapeutics, Inc. (NASDAQ:LSTA ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants John Menditto - VP, IR & Corporate Communications David Mazzo - President, CEO & Director James Nisco - SVP, Finance, Treasurer, CAO & Principal Financial and Accounting Officer Kristen Buck - EVP, R&D & Chief Medical Officer Conference Call Participants Steve Brozak - WBB Securities Pete Enderlin - MAZ Partners Will Hidell - Brookline Capital Markets Operator Welcome to the Lisata Therapeutics' Third Quarter 2024 Financial Results and Business Update Conference Call. [Operator Instructions] As a reminder, this call is being recorded today, Tuesday, November 12, 2024.
Lisata Therapeutics advances clinical trials in Q3 ahead of 'data-rich' 2025
Lisata Therapeutics Inc (NASDAQ:LSTA) reported significant advancements across its clinical portfolio in the third quarter, with multiple key data readouts projected over the next 18 months. Lisata's financial performance for the quarter showed a 10.5% year-over-year decrease in operating expenses, down to $5.3 million from $6 million.
Lisata Therapeutics and Valo Therapeutics partner in preclinical study on cancer immunotherapy
Lisata Therapeutics Inc (NASDAQ:LSTA), the US-based clinical-stage pharmaceutical company, and Finnish immunotherapy developer Valo Therapeutics Oy have announced a preclinical research collaboration to explore a novel cancer treatment combination targeting melanoma. Under the collaboration, Valo Therapeutics will lead research investigating the potential benefits of combining Lisata's experimental drug, certepetide, with Valo's PeptiCRAd immunotherapy platform and a checkpoint inhibitor.
Lisata Therapeutics partners with University of Cincinnati to investigate endometriosis therapy - ICYMI
Lisata Therapeutics Inc (NASDAQ:LSTA) chief medical officer Dr Kristen Buck discussed with Proactive a promising collaboration between the company and the University of Cincinnati aimed at investigating an endometriosis treatment. Dr Buck highlighted Certepetide, Lisata's novel cyclic peptide therapeutic that targets integrins and neuropilin receptors, which are notably elevated in both solid tumors and endometriosis.
Lisata Therapeutics, Inc. (LSTA) Upgraded to Buy: Here's What You Should Know
Lisata Therapeutics, Inc. (LSTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
